FORM 13-501F1
CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS –
PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, _Konstantin Lichtenwald_____, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

_Konstantin Lichtenwald_____   _____April 29, 2021_____

Name: Konstantin Lichtenwald   Date:

Title: CFO

Reporting Issuer Name: BioCure Technology Inc.
                                             _____

End date of previous financial year: 31.12.2020
                                             _____

Type of Reporting Issuer: [×] **Class 1 reporting**   [   ] **Class 3B reporting**
                                     issuer   **issuer**

Highest Trading Marketplace: CSE
                                     _____

Market value of listed or quoted equity securities:

Equity Symbol   CURE
                                     _____

1st Specified Trading Period (dd/mm/yy)   01.01.2020   to   31.03.2020
                                     _____   to   _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace $ _____ 0.22
                                                                                          (i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

(ii) 97,127,908

Market value of class or series

(i) x (ii) $ 21,368,139.76

(A)

2nd Specified Trading Period (dd/mm/yy) 01.04.2020 to 30.06.2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

$ 0.25

(iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

98,127,908

(iv)

Market value of class or series

(iii) x (iv) $ 24,531,977

(B)

3rd Specified Trading Period (dd/mm/yy) 01.07.2020 to 30.09.2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

$ 0.20

(v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

98,127,908

(vi)

Market value of class or series

(v) x (vi) $ 19,625,581.6

(C)

4th Specified Trading Period (dd/mm/yy)   01.10.2020 _____ to _____ 31.12.2020

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

$ _____ 0.30
(vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

_____ 98,127,908
(viii)

(vii) x (viii) $ _____ 29,438,372.4
Market value of class or series   (D)

5th Specified Trading Period (dd/mm/yy)   _____ to _____

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

$ _____
(ix)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

_____
(x)

(ix) x (x) $ _____
Market value of class or series   (E)

Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))

$ _____ 23,741,017.69
(**1**)

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined) $ _____
(**2**)

Capitalization for the previous financial year   (1) + (2) $ _____23,741,017.69_____

Participation Fee $ _____*500*_____

Late Fee, if applicable $ _____

Total Fee Payable $ _____500_____
(Participation Fee plus Late Fee)